Biospecimen Collection (NCT07003295)

Name: Biospecimen Collection trial for Recurrent Mantle Cell Lymphoma (NCT07003295)
Uploaded: 2026-10-31T17:35:32.682Z
Duration: 1 min 31 s
Description: Biospecimen Collection trial for Recurrent Mantle Cell Lymphoma (NCT07003295). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07003295.

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy: a one-minute explainerNCT070032951 min

Biospecimen Collection trial for Recurrent Mantle Cell Lymphoma (NCT07003295). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with relapsed or refractory mantle-cell lymphoma after CD19-directed CAR T-cell therapy. A BTK inhibitor must also have failed or been intolerable.

The idea: glofitamab connects T cells to CD20-bearing lymphoma cells to support immune attack. Participants receive intravenous obinutuzumab, then glofitamab infusions. Treatment lasts up to twelve 21-day cycles. Researchers assess responses, survival and serious immune or neurological side effects. Prior CD20/CD3 bispecific antibodies are excluded.

This phase 2 study plans 20 patients. The National Cancer Institute sponsors it; eleven US sites are recruiting, including Baltimore.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.